Zobrazeno 1 - 10
of 81
pro vyhledávání: '"B. Hauns"'
Autor:
Steven P. Treon, Jeffrey Matous, Meletios A. Dimopoulos, Ramón García-Sanz, Leonard T. Heffner, Jerry Ping, M. Lia Palomba, Veronique Leblond, Israel Arango-Hisijara, B. Hauns, Christian Buske, David MacDonald, Alessandra Tedeschi, Charles Herbaux, Chaim Shustik, Beatrice Mahe, Marzia Varettoni, Judith Trotman, Constantine S. Tam, Efstathios Kastritis
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, ⟨10.1200/JCO.21.00838⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, ⟨10.1200/JCO.21.00838⟩
[Purpose]: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. [Methods]: Patients had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf22dbc27262c27ea0b0c4223ab5cda3
https://pubmed.ncbi.nlm.nih.gov/34606378
https://pubmed.ncbi.nlm.nih.gov/34606378
Autor:
B. Hauns, Constantine S. Tam, Efstathios Kastritis, Israel Arango-Hisijara, Steven P. Treon, Christian Buske, Judith Trotman, Leonard T. Heffner, Alessandra Tedeschi, M. Lia Palomba, Jerry Ping, Marzia Varettoni, David MacDonald, Jeffrey Matous, Meletios A. Dimopoulos, Ramón García-Sanz, Chaim Shustik, Beatrice Mahe, Charles Herbaux, Veronique Leblond
Publikováno v:
Blood. 136:24-26
Background : Ibrutinib is a once-daily Bruton's tyrosine kinase inhibitor approved in the US and EU as either a single-agent therapy or in combination with rituximab (R) for treatment of patients (pts) with Waldenström's macroglobulinemia (WM) acros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37a5807947a96ddc6bd54ef1c1537114
https://doi.org/10.1182/blood-2020-134460
https://doi.org/10.1182/blood-2020-134460
Autor:
Beatrice Mahe, Chaim Shustik, Christian Buske, Maria Lia Palomba, David MacDonald, E Kastritis, Ramón García-Sanz, Marzia Varettoni, Judith Trotman, Veronique Leblond, Alessandra Tedeschi, E.G. Poulsen, Jianyong Li, Leonard T. Heffner, Jeffrey Matous, Charles Herbaux, Steven P. Treon, B. Hauns, Constantine S. Tam, Meletios-Athanassios Dimopoulos
Publikováno v:
Hematological Oncology. 37:235-237
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51c9ae8d0e056990a00deed30437affd
https://doi.org/10.1002/hon.47_2630
https://doi.org/10.1002/hon.47_2630
Autor:
Veronique Leblond, Judith Trotman, B. Hauns, Ramón García-Sanz, Christian Buske, E Kastritis, Meletios-Athanassios Dimopoulos, Leonard T. Heffner, Marzia Varettoni, E.G. Poulsen, Constantine S. Tam, Alessandra Tedeschi, Maria Lia Palomba, Jeffrey Matous, Chaim Shustik, Beatrice Mahe, David MacDonald, Charles Herbaux, Steven P. Treon, Jianling Li
Publikováno v:
HemaSphere. 3:260-261
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c1028d454f9ce0271553159d587e206
https://doi.org/10.1097/01.hs9.0000560744.31107.fc
https://doi.org/10.1097/01.hs9.0000560744.31107.fc
Autor:
Maria Lia Palomba, Marzia Varettoni, E.G. Poulsen, Alessandra Tedeschi, B. Hauns, Leonard T. Heffner, Christian Buske, Constantine S. Tam, Beatrice Mahe, Jianling Li, Efstathios Kastritis, Charles Herbaux, David MacDonald, Judith Trotman, Véronique Leblond, Chaim Shustik, Ramón García-Sanz, Jeffrey Matous, Meletios A. Dimopoulos, Steven P. Treon
Publikováno v:
Journal of Clinical Oncology. 37:8018-8018
8018 Background: Anemia and fatigue can impair quality of life in patients (pts) with WM. Ibrutinib (ibr) as single agent or in combination with RTX is FDA-approved for WM. In pts with RTX-refractory WM, single-agent ibr induced meaningful improvemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ea69a0255259e5ed1d7e763c3472b68
https://doi.org/10.1200/jco.2019.37.15_suppl.8018
https://doi.org/10.1200/jco.2019.37.15_suppl.8018
Autor:
Marius Horger, Tom M. Ganten, Edoardo G. Giannini, Guido Gerken, Henning Wege, Thomas Herz, B. Hauns, Marcus A. Wörns, Bernd Hentsch, Stefan W. Henning, Michael Bitzer, Armando Santoro, Astrid S. Ammendola, Stefano Pegoraro, Matthias M. Dollinger, Vincenzo Montesarchio, A. Mais, Ulrich M. Lauer, Julia Holzapfel, Franco Trevisani, Nisar P. Malek, Max E. Scheulen, Vittorina Zagonel, Jens T. Siveke, Umberto Cillo
Background & Aims No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist. This phase I/II trial investigated safety, pharmacokinetics and potential biomarkers of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bd93c56e806395c9c8a62638f98d503
https://www.ncbi.nlm.nih.gov/pubmed/26952006
https://www.ncbi.nlm.nih.gov/pubmed/26952006
Publikováno v:
Arzneimittelforschung. 49:1030-1034
The aim of the study was to evaluate the efficacy and tolerability of as well as the quality of life under treatment with 5-fluorouracil (CAS 51-21-8, 5-FU) combined with parenteral GBE 761 ONC (i.e. the ginkgo biloba special extract EGb 761) in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ea540831002a4e7d3a88df3221e23be
https://doi.org/10.1055/s-0031-1300546
https://doi.org/10.1055/s-0031-1300546
Autor:
Mary E.D. Flowers, David B. Miklos, Madan Jagasia, Hildegard Greinix, Lori Styles, Jason A. Dubovsky, Biljana Horn, Bor-Sheng Ko, B. Hauns, Ahmad Mokatrin, David A. Jacobsohn
Publikováno v:
Journal of Clinical Oncology. 35:TPS7072-TPS7072
TPS7072 Background: Chronic graft versus host disease (cGVHD) is a common complication of allogeneic stem cell transplantation, with pathophysiology involving alloreactive and dysregulated T and B cells and innate immune populations. Ibrutinib, a fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59be9b6431af80f7ae300c967889f60c
https://doi.org/10.1200/jco.2017.35.15_suppl.tps7072
https://doi.org/10.1200/jco.2017.35.15_suppl.tps7072
Autor:
A. Frost, Babett Krauss, Bernd Hentsch, Sebastian Bauer, Klaus Mross, Heike Richly, Max E. Scheulen, Roland Baumgartner, Rolf Krauss, D. Scharr, A. Mais, B. Hauns
2564 Background: 4SC-205 is a potent small molecule inhibitor of the kinesin spindle protein Eg5 with broad anti-tumour activity in vitro and in vivo. Currently, 4SC-205 is the only oral available ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::626c1d70208cee25d747ddf2b30689af
Publikováno v:
Phytotherapy Research. 15:34-38
The aim of the study was to evaluate the efficacy, tolerability and quality of life in 5-fluorouracil (5-FU) pretreated colorectal cancer patients after combined 5-FU and Ginkgo biloba extract GBE 761 ONC (i.e. the Ginkgo biloba special extract EGb 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c431464ee22d363cbfc0494cadb625ec
https://doi.org/10.1002/1099-1573(200102)15:1<34::aid-ptr755>3.0.co
https://doi.org/10.1002/1099-1573(200102)15:1<34::aid-ptr755>3.0.co